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Abstract
Background Autologous chondrocyte implantation (ACI)
is an important procedure when repairing cartilage defects
of the knee. We previously reported several basic studies
on tissue-engineered cartilage, and conducted a multicenter
clinical study in 2009. In this clinical study, we evaluated
the patients’ clinical scores and MRI findings before and
after tissue-engineered cartilage implantation, and com-
pared the data obtained at 1 year and approximately
6 years post-implantation.
Methods Fourteen patients who underwent implantation
of tissue-engineered cartilage to repair cartilage defects of
the knee were evaluated. Tissue-engineered cartilage was
produced by culturing autologous chondrocytes three
dimensionally in atelocollagen gel. The patients were
evaluated clinically using the Lysholm score, and the ori-
ginal knee-function score at pre-implantation and at 1 year
and approximately 6 years post-implantation. MRI scans
were obtained at the same observation periods. A modified
magnetic resonance observation of cartilage repair tissue
(MOCART) system was used to quantify clinical efficacy
based on the MRI findings.
Results In approximately 6 years of follow-up, none of
the 14 patients reported any subjective symptoms of con-
cern. The mean Lysholm score and the original knee-
function score (63.0 ± 10.1, 59.9 ± 5.7) significantly
improved at 1 year after implantation (86.4 ± 11.8, 94.1 ±
9.2), and were maintained until 6 years after implantation
(89.8 ± 6.2, 89.9 ± 11.2), although some patients showed
deterioration of Lysholm and original knee scores between
1 year post-implantation and the final follow-up. The mean
MOCART score was 13.2 ± 12.0 pre-implantation, and
62.5 ± 24.7 at 1 year and 70.7 ± 22.7 at approximately
6 years post-implantation. The MOCART scores at 1 year
and 6 years were significantly higher than the pre-
implantation score, but there was no significant difference
between the scores at 1 and 6 years, indicating that the
MRI results at 1 year after implantation were maintained
for the next 5 years.
Conclusions The clinical scores and MRI findings after
implantation of tissue-engineered cartilage were improved
at 1 year after implantation and were maintained until
6 years after implantation.
Introduction
There have been numerous reports on the use of cultured
cells to treat cartilage injuries of the knee. One of the most
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prominent reports, by Brittberg et al. [1], is on autologous
chondrocyte implantation (ACI). In that work, the authors
used monolayer culture to increase the number of chon-
drocytes from cartilage harvested from healthy non-
weight-bearing sites, and then transplanted these cells to
repair articular cartilage defects after covering the defects
with a periosteal flap with stitches. Although a number of
concerns relating to this conventional ACI have been
highlighted in subsequent reports, or adverse events after
implantation were reported [2–5], it appears that this new
surgical technique has now become an established proce-
dure, and excellent results have been reported [6–9].
Recently, the autologous periosteum was replaced by a
collagen membrane used as a covering material to avoid
some adverse events and the invasion of healthy tissue
[10]. Moreover, options for ACI are already commercially
available, and this treatment approach is now considered to
have become routine.
Through an assessment of normal chondrocytes cultured
three-dimensionally in agarose gel, Benya and Shaffer [11]
found that these cells maintained a cartilage-organizing
potential similar to that in living organisms without
dedifferentiation, in contrast to the results obtained in a
monolayer culture. In addition to showing that cultured
chondrocytes in atelocollagen gel maintained their carti-
lage-organizing potential, we have demonstrated the use-
fulness of this cultured cartilage in animal experiments [12,
13]. Based on these studies, we modified the conventional
ACI approach using isolated cultured chondrocytes to
devise a method for implanting tissue-engineered cartilage
using three-dimensional culture in atelocollagen gel [14].
In short, we performed transplant procedures in 28 knees
and conducted follow-ups for at least 25 months, reporting
excellent results in 26 knees. Using this technique, we
sought to address the potential disadvantages of conven-
tional ACI, such as dedifferentiation in monolayer culture
and leakage of chondrocytes. Recently, many types of
biodegradable materials have been used as scaffolding to
make three-dimensional cultured cartilage [15–17].
Approaches to the clinical evaluation of therapies for
knee injury such as ACI include subjective evaluations by
patients using various clinical scores. Two of these, the
knee injury and osteoarthritis outcome score (KOOS) [18]
and the Lysholm knee score (LKS) [19], are important
indicators for elucidating clinical usefulness. Meanwhile,
objective evaluation methods include arthroscopically-
guided diagnostic imaging and magnetic resonance imag-
ing (MRI) evaluation. The greatest advantage of MRI
evaluation is that it permits noninvasive imaging and
evaluation, and a comparison of MRI changes over time is
useful. However, since it requires specialized equipment
and is burdensome for certain patients, and moreover, since
routine evaluation indicators are not especially well
established, few reports have been published on MRI
changes in the long-term follow-up of patients who have
undergone ACI.
With the aim of further establishing the usefulness of
tissue-engineered cartilage using atelocollagen, a multi-
center study was conducted in 2009 by a group that
included the authors, in which cartilage defects of the
knee in 27 patients were treated [20]. This was conducted
as a sponsor-initiated clinical study on behalf of a com-
pany which focuses solely on regenerative medicine. In
short, the study was conducted at six orthopaedic centers
that specialize in the treatment of knees. Evaluations of
variables such as clinical symptoms and arthroscopic
findings revealed improvement according to our original
knee-function score, and arthroscopic examination yiel-
ded evaluations of normal or nearly normal results in
92 % of knees, demonstrating the usefulness of cultured
cartilage grown in three-dimensional culture using
atelocollagen.
In contrast to the number of reports on the long-term
follow-up of patients with conventional ACI [6, 7, 21],
there are few reports on the long-term follow-up of the fate
of three-dimensionally cultured chondrocytes. Further-
more, for the reasons presented above, the literature is
silent on longitudinal studies of MRI evaluations. There-
fore, for patients who were part of the multicenter study
and were then followed up at our centers, we describe in
this report a comprehensive investigation of changes over
the follow-up duration in these patients’ clinical symptoms
and MRI findings for a mean duration of at least 6.2 years
after implantation.
Materials and methods
Subjects
The subjects of this investigation were drawn from the
31 patients described in the report published by Tohyama
et al. [20]. From the 30 patients who were included in the
efficacy evaluation set, we recruited those who were
available for a 5-year follow-up at two medical institutions
in Japan.
The inclusion criteria in the clinical study conducted by
Tohyama et al. were as follows: adults aged 20 years or
older; patients with full-thickness defects of cartilage in
knees caused by trauma, or osteochondritis dissecans
(OCD) or osteoarthritis (OA); and patients who had either
failed to respond to conventional methods or for whom it
was judged that a benefit could not be anticipated. Simi-
larly, the study was conducted with appropriately-selected
exclusion criteria such as a history of rheumatoid arthritis
and other systemic diseases, or of malignant tumor.
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Patients were also subjected to intradermal testing to
establish that they were not allergic to atelocollagen gel.
From the 30 patients evaluated for efficacy in the above
multicenter study in six medical institutions, the present
follow-up research was conducted for 18 patients at two
centers. We evaluated a total of 14 patients, excluding those
who were unable to visit the centers for personal reasons.
The mean age of these evaluated patients was 33.1 years
(21–52), six being male and eight female. The causes of the
osteochondral defects were trauma (11 knees) and osteo-
arthritis (3 knees), and the mean (±SD) lesion size was 3.4
(±2.7) cm (Table 1). Two patients underwent simultaneous
surgical procedures, with concomitant reconstruction of the
medial patellofemoral ligament (case nos. 3, 10). Details of
the patients are summarized in Table 1.
Preparation of tissue-engineered cartilage
Tissue-engineered cartilage was prepared according to the
method described by Ochi et al. In short, approximately
300 mg of normal cartilage was harvested from an unloa-
ded site under arthroscopic guidance from each individual
patient and delivered to a facility belonging to Japan Tissue
Engineering Co., Ltd. (Gamagori, Japan). All tissue-engi-
neered cartilage used in this multicenter study was pre-
pared at this facility. After arrival at the facility, the
patient’s cartilage tissue was processed with collagenase
(type XI; Sigma-Aldrich, St. Louis, MO, USA) to produce
a suspension of isolated chondrocytes. The medium used
for seeding was Dulbecco’s Modified Eagle Medium
(DMEM; GIBCO Invitrogen, Carlsbad, CA, USA) sup-
plemented with 10 % fetal bovine serum (FBS) (JRH
Biosciences, St. Lenexa, KS, USA) and 20 mg of HEPES
buffer (GIBCO Invitrogen).
To perform the three-dimensional culture in atelocolla-
gen, the suspension of isolated chondrocytes in the above
medium and atelocollagen (3 % type I collagen; Koken,
Tokyo, Japan) were mixed in a 1:4 ratio and then stirred
thoroughly to produce a uniform mixture. The mixture of
thoroughly-dispersed cells and atelocollagen was added to
culture dishes using a special-purpose seeding ring, and the
dishes were heated at 37 C for 1 h to harden the gel.
The medium used for cell culture was DMEM supple-
mented with 10 % fetal bovine serum (FBS), 50 lg/ml
L-ascorbic acid phosphate magnesium salt (Nikko Chemi-
cals, Tokyo, Japan), 50 lg/ml gentamicin sulfate (Scher-
ing-Plough, Munich, Germany), 0.25 lg/ml amphotericin
B (Bristol-Myers Squibb, New York, NY, USA), and
HEPES buffer. FBS was selected in accordance with the
requirements of the Standards for Biological Ingredients
(notification no. 210 of the Japanese Ministry of Health,
Labor and Welfare).
The tissue-engineered cartilage was incubated in an
atmosphere of 5 % carbon dioxide and 95 % air at 37 C.
Table 1 Details of the 14 knee with cartilage defects treated with cultured cartilage transplantation
Case Gender Age
(years)
Height
(cm)
Body
weight
(kg)
Disease Side Site of
lesion
Size of
lesion
(cm2)
Outerbridge
grade
Number
of previous
operations
Duration
of symptoms
(months)
Follow-up;
EP II (years)
1 F 36 152 45.0 Trauma L MFC 1.3 III 0 11 6.7
2 M 26 173 74.0 Trauma L LFC 2.4 III 1 24 6.6
3a F 21 152 42.8 Trauma L Patella 2.0 IV 0 60 6.4
4 M 45 169 87.0 Trauma L MFC 2.9 IV 1 12 6.3
5 M 30 169 52.2 Trauma L MFC 2.0 IV 0 3 6.1
6 M 42 167 74.6 OA L MFC 2.4 III 0 24 6.1
7 M 23 177 75.0 Trauma R MFC 1.6 IV 1 3 6
8 F 22 168 62.0 Trauma R MFC 3.8 IV 0 3 6.6
9 F 47 160 65.0 OA R Patellar fossa 2.8 IV 1 9 6.3
Patella 1.3
MFC 0.6
10a F 21 151 45.0 Trauma L LFC 2.0 IV 0 3 6.3
11 M 40 171 91.0 Trauma R LFC 4.9 IV 1 36 6
12 F 37 160 59.0 Trauma L Patella 4.1 IV 0 3 5.9
Patellar fossa 2.9
13 F 52 162 82.0 OA L MFC 11.3 IV 0 24 5.7
14 F 22 171 44.0 Trauma L Patella 4.2 IV 1 60 5.7
OA osteoarthritis, EP II the final evaluation time, LFC lateral femoral condyle, MFC medial femoral condyle
a Reconstruction of medial patellofemoral ligament was performed simultaneously during the operation
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The culture medium, which was well qualified by means
such as a sterility test, was changed every 3–4 days. As the
cell culture progressed, the collagen became opaque and
acquired a certain level of hardness. Furthermore, cell
outgrowths were observed from the locations where the gel
was attached to the dish, and cells also became visible on
the dish surface.
Implantation of cultured cartilage
Chondrocytes were three-dimensionally cultured in atelo-
collagen gel for 28 days. The atelocollagen gel containing
these chondrocytes was used as the tissue-engineered car-
tilage for grafting. Before being shipped as tissue-engi-
neered cartilage from the culture facility, a suite of quality
tests was performed. Briefly, the results of these pre-ship-
ment quality tests consisted of a negative bacterial culti-
vation test of the medium, a negative membrane filter
sterility test, a negative Mycoplasma screening test using
polymerase chain reaction (PCR), a negative endotoxin
test, the number of viable cells (by microscopic examina-
tion to determine cell number) and the viability (with a
hemocytometer and Trypan blue staining), cellular out-
growth from the tissue-engineered cartilage, glycosami-
noglycan content, and bovine serum albumin content.
A medial or lateral parapatellar arthrotomy was carried
out under tourniquet control. The chondral lesion was
debrided as far as the normal surrounding cartilage and
until subchondral bone was visible. The defect was covered
with a sutured periosteal flap taken from the proximal
medial tibia. The flap was shaped and sutured to the sur-
rounding rim of normal cartilage with interrupted 5-0
nylon. After suturing half of the border of the flap, the
tissue-engineered cartilage was placed in the defect, and
the remaining border of the flap was sutured. The joint
capsule, retinaculum, and skin were sutured in separate
layers. The knee was supported by a lightweight brace.
Two weeks after transplantation, continuous passive
movement of the joint was begun. Partial weight-bearing
was introduced 3 weeks after surgery, and was gradually
increased to full weight-bearing with muscle training dur-
ing the first 8 weeks after surgery.
Multicenter study procedures
As described above, 14 patients treated at two medical
institutions were selected as the subjects of this study.
Before the study commenced, the ethics committees of
each university reviewed and approved the ethical validity
of the study. Written informed consent was obtained from
all patients, and the rights of the patients were protected.
All patients agreed that any results of this study would be
published. Patients selected as subjects were asked to visit
the appropriate hospital, and MRI scans were obtained after
interviews about their clinical findings at that time. Further
details of the procedures are provided below.
Evaluation by clinical outcome
To produce a score for clinical symptoms, the interview
included questions about symptoms such as motion pain,
rest pain, and knee motion, and the Lysholm–Gillquist
scores [19] were determined from the responses. These
scores were also converted to a numerical value using our
original knee-function score [20], which is optimized for
evaluating the implantation of tissue-engineered cartilage
(Table 2).
An evaluation of the clinical course was made by
comparing the scores obtained pre-implantation (pre-
operation period; PP) and at 1 year post-implantation
(evaluation period I; EP I). At each final hospital visit,
patients were asked about their clinical symptoms at the
time of evaluation [evaluation period II; EP II, 6.2
(5.7*6.7) years post-implantation].
We selected our original knee function score because, in
contrast to the Lysholm knee score (LKS), which includes
items relevant to evaluating therapeutic efficacy after lig-
ament reconstruction, such as limping and knee stability,
our score minimizes the effects of such factors and con-
siders only the effects of cartilage.
We not only inquired into the level of knee loading in daily
activities, but also ascertained whether patients had under-
gone additional surgical interventions since implantation.
Evaluation by MRI
Magnetic resonance imaging was done on a 3.0 T magnet
system (Signa EXCITE HD 3T, Signa HDx 3T; GE
Healthcare, Little Chalfont, UK). During imaging, the knee
was flexed slightly and scans were acquired under proton
density-weighted conditions. Coronal and sagittal scans
were acquired for the femoral condyle, and axial and
sagittal scans for the patellofemoral joint surface.
After imaging, a modified version of the magnetic res-
onance observation of cartilage repair tissue (MOCART)
system [22, 23] was used to score the extent of cartilage
formation at the transplanted site (Table 3). Evaluations
were done by an orthopaedic surgeon who was involved in
clinical and basic research into cultured cartilage, but was
not involved in treating the patients of this study. Multiple
defects were evaluated individually, and the worst score
was adopted as the patient MOCART score. The modifi-
cations were as follows: under the original MOCART
method, images were obtained using fast spin echo and 3D-
gradient echo-FSE sequences, while we employed a single
imaging sequence and scored a maximum of 30 points for
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items relevant to the signal intensity of the image (in the
original method, a total of 30 points, comprising 15 points
per item, was used). For the reconstructed region of
cartilage visualized on the MRI scans, the height of the
formed cartilage, the integration to the border zone, the
surface of the repaired tissue, and other variables were
Table 2 Descriptions of the Lysholm knee score and the original knee function score
Lysholm knee score Original knee-function score
Description Score Description Score
Limp Knee motion pain
None 5 No motion pain 50
Slight or periodic 3 Mild motion pain (rare, relieved) 35
Severe and constant 0 Moderate motion pain (frequent, limiting) 20
Support Severe motion pain (constant, not relieved) 0
None 5 Rest knee pain
Stick or crutch needed 2 No rest pain 25
Weight-bearing impossible 0 Mild rest pain (rare, relieved) 15
Locking Moderate or severe rest pain (frequent or constant) 0
None 15 Range of knee motion
None, but catching sensation present 10 No loss of motion 25
Occasional 6 Mild loss of motion (total are C90) 16
Frequent 2 Moderate loss of motion (total are \90) 8
At examination 0 Ankylosis 0
Stairs Total 100
No problem 10
Slight problem 6
One step at a time 2
Impossible 0
Instability
Never 25
Rarely during athletic activities 20
Frequently during athletic activities 15
Occasionally during daily activities 10
Often during daily activities 5
Every step 0
Pain
None 25
Inconstant and slight during strenuous activities 20
Marked during or after walking more than 2 km 10
Marked during or after walking less than 2 km 5
Constant 0
Swelling
None 10
After strenuous activities 5
After ordinary activities 2
Constant 0
Squatting
No problem 5
Slight problem 4
Not beyond 90 of knee flexion 2
Impossible 0
Total 100
Graft of tissue-engineered cartilage 417
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evaluated on a score with a maximum score of 100. For
these items, we compared scores obtained at three times:
pre-implantation (PP), at 1 year post-implantation (EP I),
and at the final evaluation time (EP II).
Statistical analysis
To compare the LKS and other clinical scores, as well as
the above MRI-related scores, the relationships between
the respective scores obtained at PP, EP I, and EP II were
statistically analyzed.
Multiple linear regression was used to statistically
analyze the evaluations of the LKS and MRI scores, and
Wilcoxon’s signed rank test was used to analyze the
effects at each evaluation time (PP, EP I, EP II) for the
MRI scores. Differences were considered significant at
p \ 0.05.
Results
Clinical course
At EP II (mean duration 6.2 years after implantation), none
of the 14 patients reported any subjective symptoms of
concern. However, 3 of these patients reported experienc-
ing post-implantation pain and other transient subjective
symptoms. Meanwhile, 8 patients reported engaging in
daily activities that imposed an excessive load on the knee,
such as sports or heavy physical labor, and denied any
findings of concern at such times. Moreover, no patients
had undergone any additional surgery up to 6 years post-
implantation (Table 1). In the present study, there was no
infection during the cell culture periods or after implanta-
tion, no deep thrombosis, neural or arterial involvement,
nor ossification of the grafts.
Table 3 Description of the modified MOCART score
Variable Class Score
Degree of defect repair and defect filling Complete (on a level with adjacent cartilage) 20
Hypertrophy (over the level of the adjacent cartilage) 15
Incomplete (under the level of the adjacent cartilage: underfilling)
[50 % of the adjacent cartilage 10
\50 % of the adjacent cartilage 5
Subchondral bone exposed (complete delamination or
dislocation and/or loose body)
0
Integration to border zone Complete (complete integration with adjacent cartilage) 15
Incomplete (incomplete integration with adjacent cartilage),
demarcating border visible (split-like)
10
Defect visible
\50 % of the length of the repair tissue 5
[50 % of the length of the repair tissue 0
Surface of the repair tissue Surface intact (lamina splendens intact) 10
Surface damaged (fibrillations, fissures, and ulcerations)
\50 % of repair tissue depth 5
[50 % of repair tissue depth or total degeneration 0
Structure of the repair tissue Homogeneous 5
Inhomogeneous or cleft formation 0
Signal intensity of the repair tissue Isointense 30
Moderately hyperintense 10
Markedly hyperintense 0
Subchondral lamina Intact 5
Not intact 0
Subchondral bone Intact 5
Edema, granulation tissue, cysts, sclerosis 0
Adhesions No 5
Yes 0
Effusion No effusion 5
Effusion 0
Maximum score 100
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Evaluation of clinical scores (LKS and original
knee-function score)
Both the LKS and original knee-function score improved
significantly from PP to EP I. There was no significant
difference between the scores in EP I and EP II, indicating
that this procedure lasted until approximately 6 years after
implantation, although some patients showed deterioration
of Lysholm and original knee scores between 1 year post
implantation and the final follow-up (Table 4; Fig. 1).
Evaluation by MRI findings
MOCART scores
The mean (±SD) MOCART score was 13.2 (±12.03) pre-
implantation, 62.5 (±24.71) at EP I, and 70.7 (±22.69) at
EP II (Table 4, Fig. 1). The MOCART scores at EP I and
EP II were significantly higher than the PP scores, but there
was no significant difference between the scores at EP I
and EP II.
We also evaluated various factors, including age, BMI,
and disease of the patient, site and size of the lesions, and
duration of the symptoms, which could be related to the
final clinical scores and MOCART scores. However, we
could not find any significant correlation between the
clinical or MRI scores and the factors listed above, prob-
ably due to the small number of patients (data not shown).
Case reports
Case no. 2: a male aged 26 years (at implantation),
height 173 cm and weight 74.0 kg
Two months before implantation, this patient was diag-
nosed with a traumatic cartilage defect of the lateral con-
dyle of the left femur. The LKS at PP was 79 points, and
the original knee-function score was 61 points. MRI and
arthroscopic examinations disclosed a 2.0 cm diameter
cartilage defect in the lateral condyle of the left femur,
classified as Outerbridge grade III (Fig. 2). The MOCART
score at PP was 15 (Fig. 3a, d). Four weeks before
implantation, cartilage tissue was harvested under arthro-
scopic guidance from a non-load-bearing region of the left
patellofemoral cartilage and then used to prepare tissue-
engineered cartilage, which was implanted into the carti-
lage defect in the patient’s left knee and then covered with
periosteum harvested from the right tibia. For rehabilita-
tion, CPM was started at 10 days post-implantation, partial
weight-bearing flexion motion at 31 days post-implanta-
tion, and full weight-bearing flexion motion at 61 days
post-implantation.
At EP I, the LKS was 96 points, and the original knee-
function score was 100 points. MRI scans showed that
tissue at the implanted site had slightly higher signal
intensity than that of normal cartilage. The thickness was
less than 50 % that of normal cartilage, and the MOCART
score was 35 (Fig. 3b, e).
At 6.6 years post-implantation (EP II), the LKS was
100 points, and the original knee-function score was
100 points. The signal intensity at the implanted site
was almost the same as that of surrounding normal carti-
lage except for a small low-intensity spot, and the implant
thickness was almost the same as that of the surrounding
normal cartilage. Although slight subchondral change is
seen beneath the implanted site, the MOCART score was
95 (Fig. 3c, f).
Case no. 13: a female aged 52 years (at implantation),
height 162 cm and weight 82.0 kg
Two years before implantation, the patient was diagnosed
with osteoarthritis with cartilage defect in the left medial
femoral condyle. The pre-implantation LKS was 62 points
and the original knee-function score was 66 points. MRI
and arthroscopic examinations disclosed a 4.8 9 3.0 cm
cartilage defect in the left medial femoral condyle, classi-
fied as grade IV according to the Outerbridge scheme
(Fig. 4). The MOCART score at PP was 5 (Fig. 5a, d).
At EP I, the LKS was 85 points and the original knee-
function score was 91 points. MRI scans revealed that the
cartilage defect was repaired with cartilaginous tissue with
a signal intensity comparable to normal cartilage. The
thickness of the cartilage at the site was almost the same
as that of normal cartilage. The MOCART score was 65
(Fig. 5b, e).
At 5.7 years post-implantation (EP II), the LKS was
81 points and the original knee-function score was
91 points. MRI scans showed that the surface of the
repaired tissue was slightly irregular and that the signal
intensity was nonuniform, but the thickness was main-
tained until final follow-up, although osteoarthritic change
was slightly advanced. The MOCART score was 70
(Fig. 5c, f). The femorotibial angles of this patient were
180 at PP, 176 at EP I, and 175 at EP II, indicating no
further progression of deformity.
Discussion
In this research, we obtained excellent results after
implanting three-dimensionally cultured human chondro-
cytes grown in atelocollagen gel, which were prepared
according to the method described by Ochi et al. To
date, the findings have suggested that post-implantation
Graft of tissue-engineered cartilage 419
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Table 4 Clinical outcome
scores and MRI findings for
each patient
PP pre-implantation,
EP I at 1 year post-
implantation, EP II at the final
evaluation time (EP II)
Lysholm knee score Original knee-function score MRI score
Case PP EP I EP II PP EP I EP II PP EP I EP II
1 54 96 80 51 100 66 30 80 75
2 79 96 100 61 100 100 15 35 95
3 81 95 86 66 100 100 20 75 85
4 73 91 86 61 100 100 5 70 90
5 65 95 95 61 100 100 5 75 75
6 43 58 80 51 85 75 5 15 15
7 58 81 90 70 100 90 10 85 70
8 64 74 90 60 75 85 5 75 80
9 64 71 94 51 76 75 10 55 75
10 61 91 96 61 100 100 5 80 80
11 65 85 90 60 91 100 5 10 75
12 52 91 85 60 100 76 20 75 25
13 62 85 81 66 91 91 5 65 70
14 61 100 90 60 100 100 45 80 80
PP: pre-implantation, EP I: at 1 year post-implantation, EP II:  at the final evaluation time (EP II).
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formation of cartilage-like tissue is excellent, similar to the
results obtained for autologous cartilage implantation
(ACI) prepared in monolayer culture, as described by
Brittberg et al. [1], although the histological findings of the
repaired tissues were not examined in the present study to
avoid damaging the repaired tissues. Furthermore, during
our 6-year post-implantation evaluation period, no patients
required further surgery. According to the comparative
evaluation by Knutsen et al. [3], further surgery was
required in 23 % of patients at 60 months after both ACI
and microfracture treatment. During follow-up to
37 months described by Saris et al. [24], further surgery
was required in 3.9 % of patients receiving characterized
chondrocyte implants and 11.5 % of patients receiving
microfracture surgery. Given these published results, it is
clear that the results of long-term follow-up for our method
were excellent, and compare favorably to those in previous
reports on ACI.
By contrast, post-approval surveillance data for ACI in
the United States show that adverse events were reported in
294 patients (497 events) in the period from 1996 to 2003.
The most common adverse event was graft failure, reported
in 73 patients (24.8 %), followed by delamination in
65 patients (22.1 %), tissue hypertrophy in 52 patients
(17.7 %), and local infection in 21 patients (7.1 %) [5]. As
there was no record of the total number of implantations,
the incidence of adverse events cannot be calculated.
Nevertheless, the adverse events that occurred were mainly
associated with delamination or hypertrophy, and while the
number of events was low, infection was also reported. In
the report by Peterson et al. [21] describing research in
which 94 patients were followed for 2–9 years after
undergoing ACI, similar results were also obtained, with
hypertrophy reported in 26 patients (27.6 %) and graft
failure in 7 patients (7.4 %). In the earlier report of our
research results, graft failure was reported in 2 of 31 sub-
jects up to 1 year post-implantation. Of these 2 cases of
graft failure, excessive flexion was forced in 1 case, and a
hypertrophied portion became delaminated in the other.
These findings were similar to many other case reports.
Fortunately, transient pain was subsequently reported by
Fig. 2 Case no. 2, a 26-year-old male. Arthroscopic view showing a
2.0 cm diameter traumatic cartilage defect in the lateral condyle of
the left femur, classified as Outerbridge grade III
Fig. 3 Case no. 2. There were
cartilage defects (arrowhead) in
the lateral condyle of the left
femur (a, d). One year after
operation, the thickness of the
graft area was less than 50 % of
that of normal cartilage
(arrowhead) (b, e). At 6.6 years
post-implantation, the signal
intensity at the implanted site
was almost the same
(arrowhead) as that of
surrounding normal cartilage
(c, f)
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only 2 patients up to the end of the present evaluation
period, no patients required revision surgery during our
follow-up, and no obvious adverse events were reported.
Usually, when evaluating treatment methods such as
those described in this report, it is preferable to conduct a
comparative study such as a randomized controlled trial
(RCT). A number of reports describe efficacy evaluations
of ACI made via RCTs [24, 25]. Unfortunately, for reasons
associated with health insurance and other considerations,
it would be difficult to conduct a complete RCT in Japan,
and we were also unable to use such a design in the present
clinical study. In brief, the reasons for not conducting an
RCT included the following key ethical concerns. (1)
Because implantation of tissue-engineered cartilage
involves tissue being harvested for culture, it necessitates a
different protocol from that of microfracture surgery alone,
and the element of blinding is therefore lost. (2) Post-
Fig. 4 Case no. 13, a 52-year-old female. Arthroscopic view showing
a 4.8 9 3.0 cm cartilage defect in the left medial femoral condyle,
classified as Outerbridge grade IV
Fig. 5 Case no. 13. An
osteoarthritic cartilage defect
occurred in the medial condyle
of the left femur (arrowhead)
(a, d). One year after operation,
MRI showed that the thickness
of the cartilage at the graft site
(arrowhead) was almost the
same as that of normal cartilage
(b, e). At 5.7 years post-
implantation, the thickness of
the graft site (arrowhead) was
maintained, although
osteoarthritic change was
slightly advanced (c, f)
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implantation follow-up would also require unnecessary
arthroscopic examination to be conducted routinely in the
control group of patients. (3) Patients who are seeking
treatment with tissue-engineered cartilage would not be
able to receive their desired treatment. (4) Minas et al. [26]
reported problems with the prognosis for patients who were
scheduled to undergo ACI if they had already received
microfracture surgery beforehand. Hence, by using an MRI
evaluation (given its relatively low level of invasiveness) in
this study, we sought to ascertain the superiority of the
treatment by observing changes from 1 to 6 years post-
implantation, in addition to long-term follow-up for
6 years.
Quantifying joint cartilage defects or the state of their
repair is difficult with MRI scans, and there have been
almost no routinely established methods. To address this
situation, Domayer et al. proposed a scoring system (MO-
CART score) that aimed to produce an objective evaluation
using MRI scans [23]. Their method encompasses a com-
prehensive point score for examining MRI scans in post-
implantation evaluation of repaired cartilage. This scoring
system includes the height and signal intensity of the
repaired cartilage, the state of integration with the sur-
rounding tissue, the condition of the surface, and the state of
formation of subchondral bone, which we believed was also
the most appropriate indicator in our research. However,
since an MRI imaging procedure for obtaining all of these
evaluations was unavailable at the start of our study, we
modified the method to comprise one type of imaging
sequence to assess the signal intensity of the repair tissue.
As previously noted, our research is a comparison of the
conditions at 1 year and 6 years post-implantation against
that before implantation. Hence, as mentioned above, we
were unable to use the results of our research to directly
determine its superiority over other treatment methods.
However, we were able to obtain findings that were not
seen in earlier reports, such as temporal changes in MRI
findings at each evaluation visit. The statistical analysis
revealed no significant differences between the MRI find-
ings at 1 year post-implantation and those at 6 years post-
implantation, suggesting that the therapeutic benefit had
been maintained. Although there were no statistically sig-
nificant differences between the MOCART scores in EP I
and EP II, we found a tendency for the scores to improve.
Of course, we cannot draw any definitive conclusions from
this study alone, and there is the possibility that this may be
a characteristic of tissue-engineered cartilage implantation,
because its condition after conventional cartilage repair
procedure is anticipated to worsen. We definitely need
more patients with a longer follow-up in the future to
clarify this issue.
It could be claimed that the number of patients was not
especially large and that the follow-up period was relatively
short in the present study. Moreover, a retrospective
approach was used for the MOCART score. Since the
images required for the original method were unavailable, it
was not possible to faithfully adhere to the original method,
and hence a modified method was employed. To further
improve the technique of implantation of tissue-engineered
cartilage, it will now be necessary to accumulate more
cases, and to conduct comparative analyses of variables
such as MRI findings and various patient characteristics,
severity of disease, and post-implantation management.
In our study, no patients required revision surgery after
implantation, and the therapeutic outcomes were relatively
stable from 1 year to about 6 years after implantation.
These results could be attributed to the fact that the surgeons
involved in the diagnosis and surgical procedure were well
versed in this treatment method, and that the conditions of
the operative procedure were adequately controlled.
Moreover, the tissue-engineered cartilage used in our study
was prepared at a rigorously controlled cell processing
center, and was only supplied to the study after assuring
quality via post-culture tests. To achieve clearance in rela-
tion to various biohazards and to minimize immunogenic-
ity, a recommended rinsing step with residual serum was
performed and a specified value for bovine serum albumin
was imposed to assure safety. Moreover, standards for
glycosaminoglycans (GAG) and type II collagen as well as
the viable cell rate together with other variables were also
used to assure efficacy. Under this control framework, the
implanted tissue used in this research met all of the prede-
termined specification values. To stabilize the clinical out-
comes achieved using this cultured cartilage in the future, it
will be critically important to not only improve the surgical
techniques and diagnostic capability of the surgeons and the
safety of the cultured tissue used in implantation, but also to
identify the efficacy parameters that can be used to establish
performance.
In conclusion, although some patients showed deterio-
rations in their Lysholm and original knee scores between 1
year post-implantation and the final follow-up, we con-
firmed that the average clinical scores and MRI findings
after implantation of tissue-engineered cartilage were
improved at 1 year after implantation and were maintained
until 6 years after implantation, indicating that our proce-
dure has mid-term longevity.
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